Stepping into your 60s is the perfect time to refresh your look with a haircut that works with your lifestyle, not against it. The right cut adds volume where hair may have thinned, brings softness ...

If you’re 60 or older and experience joint pain, that’s understandable. According to the Institute for Healthcare Policy and Innovation, 60 percent of adults ages 50 to 80 have arthritis, with half ...

A Chicago nonprofit, in conjunction with the American Federation of Teachers, is suing the U.S. Department of Education over funding cuts to a program that has long provided wraparound services to ...

White House Deputy Chief of Staff Stephen Miller called for CBS staffers engaged in a “revolt” over a 60 Minutes immigration report to be “fired” immediately. During Miller’s Fox News appearance, he ...

Gilead Sciences GILD recently announced that it has exercised its combined option to exclusively license Assembly Biosciences’ ASMB herpes simplex virus (HSV) helicase-primase inhibitor programs. The ...

In a hilarious moment, a student was knocked over by the powerful recoil of a fire hose during a training exercise. Leslie Salud and her classmate, both dressed in heavy personal protective equipment, ...

‘60 Minutes’ is back in the spotlight: The CBS logo at the entrance to its headquarters, in New York Dec. 6, 2018. (AP Photo/Mark Lennihan, File) CBS News abruptly yanked a “60 Minutes” segment on ...

(RTTNews) - Gilead Sciences (GILD) and Assembly Biosciences (ASMB) announced Gilead has exercised its combined option to exclusively license Assembly Bio's herpes simplex virus helicase-primase ...

– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years – “At Gilead, we develop novel antiviral ...

Terms of the Transaction Under the terms of the 2023 collaboration agreement between Gilead and Assembly Bio, Assembly Bio will receive a $35 million payment for Gilead’s exercise of the combined HSV ...

– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years – Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly ...